Table 2.
Bone grafting outcome
| Author | Surgical procedures | Hips, n | Mean age (years) | Mean follow-ups (range) (years) | Definition of failure | |
|---|---|---|---|---|---|---|
| NVBG | ||||||
| Level I | ||||||
| Yang et al.[74] | Phemister technique | 56 | 38.6 | NR (3.0–6.5) | Conversion into THA or onset/progression of collapse or progressive osteoarthritis | |
| Level III | ||||||
| Steinberg et al.[60] | Phemister technique | 312 | NR | NR (2–14) | Conversion to THA | |
| Level IV | ||||||
| Zhang et al.[56] | Phemister technique | 85 | 31.4 | NR (2–NR) | Disease progression | |
| Wei and Ge[75] | Phemister technique | 223 | 33.5 | 2.0 (0.6–3.5) | A Harris hip score of <80 | |
| Wang et al.[76] | Light bulb technique | 138 | 32.4 | 2.1 (0.6–3.5) | A Harris hip score of <80 | |
| Zuo et al.[61] | Light bulb technique | 119 | NR | 2.8 (0.3–5.4) | Conversion into THA or onset/progression of collapse or progressive osteoarthritis or a Harris hip score of <70 | |
| VBG | ||||||
| Level III | ||||||
| Feng et al.[67] | Vascularized fibular grafting | 60 | 37 | 2.2 (2.0–3.2) | A Harris hip score of <80 | |
| Yen et al.[66] | Vascularized fibular grafting | 39 | 40 | NR (3–NR) | Disease progression | |
| Vascularized iliac grafting | 22 | 38 | NR (4–NR) | Disease progression | ||
| Level IV | ||||||
| Ding et al.[64] | Vascularized fibular grafting | 78 | 27.8 | 5.6 (2–NR) | Disease progression | |
| Aoyama et al.[65] | Vascularized iliac grafting | 9 | 31.7 | 2 | Disease progression | |
| Zeng et al.[68] | Vascularized iliac grafting and greater trochanteric flap | 64 | 31 | 3 (1–5) | A Harris hip score of <80 | |
| Yin et al.[70] | Vascularized fibular grafting | 14 | 34 | 3.3 (1.5–4.2) | Conversion into THA or a Harris hip score of <70 | |
| Chen et al.[73] | Vascularized iliac grafting | 33 | 37 | 5.8 (0.7–13.8) | Conversion into THA | |
| Dailiana et al.[72] | Vascularized fibular grafting | 86 | 35 | 4.0 (0.6–13.7) | Conversion into THA | |
| Author | Precollapse stage disease | Pericollapse stage disease | Postcollapse stage disease | |||
| Number | Survivorship | Number | Survivorship | Number | Survivorship | |
| NVBG | ||||||
| Level I | ||||||
| Yang et al.[74] | 48 | 91.70% | 8 | 50.00% | NR | NR |
| Level III | ||||||
| Steinberg et al.[60] | 198 | 68.20% | 13 | 76.90% | 95 | 49.50% |
| Level IV | ||||||
| Zhang et al.[56] | 71 | 90.10% | 9 | 88.90% | 5 | 25.00% |
| Wei and Ge[75] | 134 | 77.60% | 89 | 85.50% | NR | NR |
| Wang et al.[76] | 67 | 74.60% | 71 | 62.00% | NR | NR |
| Zuo et al.[61] | 27 | 74.10% | 105 | 83.80% | 26 | 38.50% |
| VBG | ||||||
| Level III | ||||||
| Feng et al.[67] | 12 | 91.70% | 28 | 85.70% | 20 | 45.00% |
| Yen et al.[66] | 11 | 72.70% | 12 | 66.67% | 16 | 37.50% |
| 4 | 100.00% | 11 | 81.82% | 7 | 71.43% | |
| Level IV | ||||||
| Ding et al.[64] | 19 | 78.95% | 36 | 80.56% | 23 | 65.22% |
| Aoyama et al.[65] | NR | NR | 5 | 100.00% | 4 | 50% |
| Zeng et al.[68] | 16 | 100.00% | 22 | 90.90% | 26 | 76.92% |
| Yin et al.[70] | 3 | 100.00% | 9 | 89.00% | 2 | 50.00% |
| Chen et al.[73] | NR | NR | 26 | 30.77% | 7 | 0.00% |
| Dailiana et al.[72] | 8 | 50.00% | 15 | 73.33% | 63 | 57.14% |
THA: Total hip arthroplasty; NR: Not reported; VBG: Vascularized bone grafting; NVBG: Non-VBG.